Peregrine Pharmaceuticals Inc., of Tustin, Calif., reported a 23.2-month median overall survival (OS) from a single-arm Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in patients with locally advanced or metastatic breast cancer.